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Abstract
Objectives The purpose of this in vitro study was to determine
the antimicrobial activity of two different taurolidine gel for-
mulations in comparison with minocycline microspheres.
Methods Three percent taurolidine gel (TLG3) and 2 %
taurolidine gel (TLG2) were compared to minocycline micro-
spheres (MINO) against single bacterial species and a 12-spe-
cies-mixture. The antimicrobial activity was proven by deter-
mination of minimal inhibitory concentrations (MICs), killing
assays, after exposure of the antimicrobials as well as within a
biofilm.
Results TheMICs against the single species were between 0.5
and 2 mg/ml of taurolidine. MICs of the used mixed microbi-
ota were 1.5 mg/ml (TLG3) and 4 mg/ml (TLG2).
Fusobacterium nucleatum and Porphyromonas gingivalis
were completely killed by 10 % TLG3 and TLG2 (equivalent
to 3 and 2 mg/ml taurolidine) after 6 h. The mixture of 12
species was not completely killed by any of the test sub-
stances. Taurolidine gels showed a post-antimicrobial activity,
however being less than that of MINO. On biofilms,
taurolidine gels reduced concentration dependently the colony
forming unit (CFU) counts (multi-species biofilms by
3.63 log10 after 100 % (30 mg/ml) of TLG3), reductions were
2.12 log10 after MINO (1000 μg/ml minocycline).
Conclusions Taurolidine gel formulations exert antimicrobial
activity against bacteria associated with periodontal disease.
Nevertheless, a complete elimination of biofilms seems to be
impossible and underlines the importance of mechanical re-
moval of biofilms prior to application of the antimicrobial.
Clinical relevance Taurolidine gels may represent a potential
alternative for adjunctive topical antimicrobial treatment in
periodontitis and infectious peri-implant diseases.
Keywords Taurolidine . Periodontal therapy . Antimicrobial
activity . Biofilm
Introduction
The antimicrobial activity of taurolidine has been known for
about 30 years. Taurolidine, a synthetic derivative of taurine,
is described as an unstable molecule in aqueous solution;
masked methanal is released which inactivates endotoxin
[1]. The breakdown products methylol-taurultam and
methylol-taurineamide are responsible for the antimicrobial
action such as interaction with peptidoglycan [2]. Another
breakdown product is taurine [2]. Taurine reacts with
hypochlorous acid to taurine chloramine which can modify
immune response [3].
The first indication for taurolidine was the prevention and
treatment of peritonitis [4]. More recently, it has gained in-
creased attention as a potential alternative in the treatment of
dental infections. Results from ex vivo studies have provided
evidence for the effectiveness of 2 % taurolidine in killing
supragingival dental plaque [5] and, combined with mechan-
ical treatment, in removal of biofilms from titanium specimens
[6]. In comparison with chlorhexidine, taurolidine was less
toxic to osteoblast-like cells and human gingival fibroblasts
adhering to titanium surfaces [7].
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In a first in vitro study, we compared a 2 % taurolidine
solution with a 0.1 % chlorhexidine digluconate solution in
different dilutions [8]. The minimal inhibitory concentrations
(MICs) of taurolidine were all below 5% of the normally used
concentration of that substance with the exception of Candida
albicans. These findings confirm those from an earlier study
which determined MIC values against seven oral plaque spe-
cies, among them one Fusobacterium nucleatum and one
Prevotella intermedia strain, and which has also revealed low-
er MIC values (dilution) for chlorhexidine compared to
taurolidine [9].
Furthermore, our previous results have also indicated that
taurolidine is active in a serum-rich environment in contrast to
the activity of chlorhexidine that was dramatically decreased.
Similar effects have been described before [10] and are of
importance since gingival crevicular fluid contains up to
35 % of the albumin found in serum [11]. In a subsequent
study, we compared taurolidine with minocycline against se-
lected species associated with periodontitis and against a
multi-species mixture consisting of 12 species [12]. The work-
ing concentration was chosen up to 50 % of the minimal
bactericidal concentration (MBC) against the mixed popula-
tion in planktonic stage. The results have also demonstrated a
comparable or even better activity than those of minocycline.
When topical application of antibiotics is considered, the
choice of controlled released devices is essential to overcome
potential problems related to the high turnover of gingival
crevicular fluid [13]. Usually, topical antibiotics are formulat-
ed as gels [14, 15] or microspheres [16] to be effective.
The purpose of the present study was to determine the
antimicrobial effect of two taurolidine gel formulations in
comparison with minocycline microsphere. The hypothesis
was that taurolidine gel acts as antimicrobial like minocycline
microspheres on microbial species associated with periodon-
titis and peri-implantitis. The antimicrobial activity was tested
in killing assays, after exposure of the antimicrobials as well
as within a biofilm.
Material and methods
Substances
As substances, a 3 % (w/w) taurolidine gel (TLG3 equivalent
to 30mg/g taurolidine) and a 2% (w/w) taurolidine gel (TLG2
equivalent to 20 mg/g taurolidine; Geistlich Pharma AG,
Wolhusen, Switzerland) were tested. As controls, minocycline
microspheres (MINO, 1 mg; Arestin®, OraPharma Inc., North
Bridgewater, NJ, USA), vehicles of TLG3 and TLG2
(Geistlich Pharma AG), and dH2O were used. All substances
including the controls were diluted in dH2O containing 0.1 %
v/v Tween 20. A twofold dilution series was always prepared
from the 2 and 3 % taurolidine gels as well as from
minocycline microspheres. Vehicles were only tested in an
amount used equivalent to the highest tested concentration
of taurolidine.
The used concentrations were based on the volume of a
doxycycline gel to be placed into the pocket which was about
100 μl [17].
Microorganisms
The following bacterial strains were tested as single bacterial
species: Aggregatibacter actinomycetemcomitans Y4,
Porphyromonas gingivalis ATCC 33277, F. nucleatum
ATCC 25586, and Streptococcus gordonii ATCC 10558.
The mixed microbiota consisted of the following bacterial
strains: Streptococcus gordonii ATCC 10558, Actinomyces
naeslundii ATCC 12104, F. nucleatum ATCC 25586,
Campylobacter rectus ATCC 33238, Eubacterium nodatum
ATCC 33099, Eikenella corrodens ATCC 23834, Prevotella
intermedia ATCC 25611, Parvimonas micra ATCC 33270,
Porphyromonas gingivalisATCC 33277, Tannerella forsythia
ATCC 43037, Treponema denticola ATCC 35405, and
Aggregatibacter actinomycetemcomitans Y4.
Before an experiment, all strains (except for Treponema
denticola ATCC 35405) were precultivated on Schaedler agar
plates (Oxoid, Basingstoke, UK) with 5 % sheep blood in an
anaerobic atmosphere or with 5 % CO2 (Aggregatibacter
actinomycetemcomitans Y4 and Streptococcus gordonii
ATCC 10558). Treponema denticola was maintained in mod-
ified mycoplasma broth (BD, Franklin Lake, NJ) added by
1 mg/ml glucose, 400 μg/ml niacinamide, 150 μg/ml
spermine tetrahydrochloride, 20 μg/ml Na isobutyrate
enriched with 1 g/ml cysteine, and 5 μg/ml cocarboxylase in
anaerobic conditions.
Determination of the minimal inhibitory concentrations
and minimal bactericidal concentrations
First, the MICs of taurolidine gels and MINO against the four
single selected species as well as against the mixed population
were determined.
Microbroth dilution technique was used for determination
ofMICs. After subcultivation of bacterial strains and checking
of purity, a defined inoculum was added to Wilkins-Chalgren
broth (Oxoid, Basingstoke, UK) containing defined concen-
trations of the antimicrobials (negative control, no agent as
well as vehicles of the gels; positive control, MINO in twofold
series dilution starting from 125 μg/ml minocycline).
Taurolidine gels were tested in a twofold dilution series
starting from 20 % of the gels (equivalent to 60 and 40 mg/ml
of taurolidine, respectively). In part, 25 % inactivated serum
(final concentration) was added. After an incubation time of
24 h, the growth of microbes was analyzed by visual checking
of turbidity. MIC was determined as the lowest concentration
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without visible turbidity of the broth and/or reduction of the
initial inoculum of the colony forming units (CFU) on the agar
plates. The MBC was the lowest concentration without any
growth of the subcultivations on the agar plates (equivalent to
a reduction by 99.9 % of the initial inoculum). Experiments
were made at least in independent duplicates.
Killing
A defined inoculum of microorganisms (5×107) was prepared
in nutrient media (Wilkins-Chalgren broth). The test sub-
stances were added. Taurolidine gels were tested in a twofold
dilution series starting from final concentrations of 10% of the
gels (equivalent to 30 and 20mg/ml of taurolidine, respective-
ly) up to 1.25 % and of 1000 μg/ml up to 125 μg/ml
minocycline (in MINO).
After 30 min and 1, 2, 4, 6, and 24 h of incubation, the
numbers of viable bacteria were determined by enumeration
of colony forming units (CFU). (In case of the mixed micro-
biota, only the total numbers of CFU were counted.)
Substantivity (growth inhibition after exposure)
Microorganisms (about 108/ml) were exposed to antimicro-
bials in 500 μl of Wilkins-Chalgren broth for 2 h.
Taurolidine gels and MINO were tested in the same concen-
trations as described for killing assays. After that, the suspen-
sions were centrifuged for 10 min at 5000g. The supernatant
was removed and 5 ml of nutrient broth (Wilkins-Chalgren
broth) was added. The CFU counts were determined after 1,
2, 6, and 24 h.
Activity of taurolidine gel against bacteria within biofilms
I n t h e s e e x p e r i m e n t s , A g g r e g a t i b a c t e r
actinomycetemcomitans Y4 and Porphyromonas gingivalis
ATCC 33277 were used to form a single-species biofilm. In
addition, a multi-species biofilm consisting of the 12 species
was established. First, the wells of 24-well plates were cov-
ered with 100 μl of 25%v/v inactivated human serum/well for
1 h. Then, 1 ml of bacterial suspension was added. The medi-
um was Brain-Heart Infusion broth (Oxoid Ltd.) with 5 %
blood (and 5 μg/ml cocarboxylase for the mixed population).
The 24-well plates were incubated in the appropriate atmo-
sphere. After 60 h, the medium was carefully exchanged. In
case of the mixed biofilm, Porphyromonas gingivalis ATCC
33277, Tannerella forsythia ATCC 43037, and Treponema
denticola ATCC 35405 were again added to the nutrient me-
dium before application to the wells. The renewed addition of
selected bacterial strains guaranteed a sufficient number of
these species within the biofilms.
After an additional incubation for 48 h, the medium was
removed carefully, and 100 μl of the gels in different
concentrations and MINO in suspension were added to the
biofilm for 1 h in the appropriate incubation. The gels were
prepared on sterile paper discs, thus allowing testing up to
100 % of the gel formulations. However, minocycline micro-
spheres could not be adequately dissolved; here the highest
tested concentration was only 1000μg/ml. After 1 h, 900μl of
Wilkins-Chalgren broth supplemented with 5 % sheep blood
(and 5 μg/ml cocarboxylase for the mixed population) was
added. This simulates in part in vivo conditions, where a di-
luting effect of subgingivally applied antimicrobials can be
assumed. The plates were incubated in the appropriate atmo-
sphere overnight (18 h). Then, the medium was removed.
Finally, the biofilm was carefully scraped and mixed by pipet-
ting, and CFU were enumerated after serial dilutions, spread-
ing of each 25 μl on agar plates, and incubation for 48 h
(Aggregatibacter actinomycetemcomitans Y4) and 7 days
(Porphyromonas gingivalis ATCC 33277 and mixed
microbiota).
Moreover, the potential inhibition of biofilm formation by
the antimicrobials was tested. For this purpose, wells were
covered with 100 μl of the antimicrobials (12.5 % of the gels
as well as 125 μg/ml minocycline) first. Thereafter, the bio-
film was formed as described above for 24 and 48 h. At these
time points, the CFU counts were determined.
The experiments were made in independent triplicates.
Results
Minimal inhibitory and minimal bactericidal
concentrations
The MICs and MBCs of taurolidine against the four single
species were between 0.5 and 2 mg/ml and between 1 and
3 mg/ml of taurolidine when testing both taurolidine gel for-
mulations. When adding 25 % serum, the MICs were equal or
one step higher. The used mixed microbiota was less sensitive
to taurolidine; MIC was 1.5 mg/ml (TLG3) and 4 mg/ml
(TLG2); the MBCs were 4–6 mg/ml. When adding serum,
MICs were similar, whereas taurolidine was not bactericidal
within the tested concentrations of 4 and 6 mg/ml. The vehi-
cles did not show any growth inhibitory effect. Sensitivity of
the included stains varied against minocycline; the highest
MICs and MBCs were 63 μg/ml. The results are presented
in Tables 1 and 2.
Considering the concentration of taurolidine in the formu-
lations, the results mean that the MICs of the TLG3 formula-
tion were up to 5 % of the formulation except for the mixed
microbiota with serum (10%).MBCs of TLG3 did not exceed
10 % of the formulation for the single species whereas it was
higher than 20 % of the formulation against the mixed micro-
biota with serum. TheMICs of the TLG2 formulation were up
to 10 % of the formulation except for the mixed microbiota
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with serum (20 %). MBCs of TLG2 were up to 20 % of the
formulation for the single species; it was higher than 20 % of
the formulation against the mixed microbiota with serum.
Killing of planktonic bacteria
F. nucleatum ATCC 25586 and Porphyromonas gingivalis
ATCC 33277 were completely killed by the highest used con-
centrations of 10 % TLG3 and TLG2 (equivalent to 3 and
2 mg/ml taurolidine) after 6 h. In case of Streptococcus
g o rd o n i i ATCC 105 5 8 a n d Ag g re g a t i b a c t e r
actinomycetemcomitans Y4, the respective times were 2 and
4 h (TLG3) and 4 and 6 h (TLG2), suggesting a higher sensi-
tivity of these strains to the antimicrobials’ killing. After 2 h,
minocycline microspheres in the concentration of 1000 μg/ml
killed all tested single strains except for Aggregatibacter
actinomycetemcomitans Y4 which was eradicated after 6 h
by all tested concentrations of minocycline microspheres.
Focusing on the mixture of 12 selected bacterial species
associated with periodontitis, neither taurolidine gels nor
MINO was able to kill completely all bacteria; in comparison
with the control, the reductions were 3.61 log10 CFU for 10%
TLG3 (3 mg/ml taurolidine), 2.89 log10 CFU for 10 % TLG2
(2 mg/ml taurolidine), and 4.77 log10 CFU for MINO
(100 μg/ml minocycline). The vehicles of both gel
formulations did not influence the growth of the single strains
and the bacterial mixture (Fig. 1).
Post-antibiotic (depot) effect
Bacteria were exposed to the antimicrobial formulations for
2 h; thereafter, the media were replaced by a medium free of
antimicrobial agents. This procedure should show a possible
depot effect of the antimicrobials. Immediately after exposure
to 10 % (3 mg/ml taurolidine) of the TLG3 formulations, no
viable Porphyromonas gingivalis ATCC 33277 and
F. nucleatum ATCC 25586 were found, 10 % (2 mg/ml
taurolidine) of the TLG2 eradicated F. nucleatum ATCC
25586 immediately, whereas Porphyromonas gingivalis
ATCC 33277 was killed only after 24 h. No complete killing
was found in case of S. gordonii ATCC 10558 and
Aggregatibacter actinomycetemcomitans Y4. MINO in its
tested highest concentrations eradicated all viable bacteria at
the latest after 6 h. Vehicles in part slightly decreased transi-
tory the growth of bacteria, e.g., the TLG2 vehicle reduced the
CFU counts of Aggregatibacter actinomycetemcomitans Y4
by about 2 log10 CFU immediately after exposure and 1 h of
growth (Fig. 2).
The antimicrobials reduced CFU counts of the mixture in a
concentration-dependent manner but were unable to kill
Table 1 Minimal inhibitory concentration (MIC) values of taurolidine
within the 3 % (TLG3) and the 2 % (TLG2) formulations as well as of
minocycline within the minocycline microspheres (MINO) against
selected oral species and a bacterial mixture consisting of 12 different
species associated with periodontitis
mg/ml of taurolidine (TLG3) mg/ml of taurolidine (TLG2) μg/ml minocycline (MINO)
w/o serum with 25 % serum w/o serum with 25 % serum w/o serum with 25 % serum
S. gordonii ATCC 10558 1.5 1.5 2 2 8 4
A. actinomycetemcom. Y4 0.75 1.5 0.5 1 31 31
P. gingivalis ATCC 33277 0.75 1.5 0.5 2 31 31
F. nucleatum ATCC 25586 1.5 1.5 1 1 16 31
12 species (mixed) 1.5 3 4 4 63 31
Table 2 Minimal bactericidal concentration (MBC) values of
taurolidine within the 3 % (TLG3) and the 2 % (TLG2) formulations as
well as of minocycline within the minocycline microspheres against
selected oral species and a bacterial mixture consisting of 12 different
species associated with periodontitis
mg/ml of taurolidine (TLG3) mg/ml of taurolidine (TLG2) μg/ml minocycline (MINO)
w/o serum with 25 % serum w/o serum with 25 % serum w/o serum with 25 % serum
S. gordonii ATCC 10558 3 3 4 2 63 31
A. actinomycetemcom. Y4 1.5 1.5 0.5 1 63 63
P. gingivalis ATCC 33277 1.5 3 1 2 63 31
F. nucleatum ATCC 25586 1.5 1.5 2 2 16 31
12 species (mixed) 6 >6 4 >4 63 63
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completely bacteria after an exposure of 2 h. The CFU count
reductions were 2.34 log10 CFU immediately after exposure
to 10 % of TLG3 (3 mg/ml taurolidine), 1.79 log10 CFU after
10 % of TLG2 (2 mg/ml taurolidine), and 2.63 log 10 CFU
after MINO (1000 μg/ml minocycline). After 24 h, the respec-
tive values were 1.93 log10 CFU for 10 % of TLG3 (3 mg/ml
taurolidine), 1.94 log10 CFU for 10 % of TLG2 (2 mg/ml
taurol id ine) , and 4.89 log 10 CFU after MINO
(1000 μg/ml). The vehicles of the taurolidine gels did not
influence the bacterial growth (difference always
≤0.5 log10 CFU) (Fig. 2).
Activity on biofilms
On 4.5-day-old biofilms, taurolidine acted clearly concentra-
tion dependently; the TLG3 formulations were more active
than TLG2. In single-species biofilms, Aggregatibacter
actinomycetemcomitans Y4 was not detectable after exposing
to 25–100 % (7.5–30mg/ml taurolidine) of the TLG3 and 50–
100 % (10–20 mg/ml taurolidine) of the TLG2; the CFU
counts of the Porphyromonas gingivalis ATCC 33277
biofilms were reduced after application of 50 and 100 % of
the TLG3 and 100 % of the TLG2 by about 6.5 log10 CFU.
Minocycline in a concentration of 1000 μg/ml killed
Aggregatibacter actinomycetemcomitans Y4 within biofilm,
but no activity was found on Porphyromonas gingivalis
ATCC 33277 biofilms. The reduction of the CFU counts in
the multi-species biofilms was 3.63 log10 CFU after applica-
tion of 100 % of TLG3 taurolidine gel and 2.62 log10 CFU
after 100 % of TLG2 taurolidine gel. MINO (1000 μg/ml
minocycline) reduced the CFU by 2.12 log10 (Fig. 3).
T h e b i o f i lm f o rma t i o n o f Agg re ga t i b a c t e r
actinomycetemcomitansY4 and of Porphyromonas gingivalis
ATCC 33277 was clearly disrupted after coating the plates
with 12.5 % of taurolidine gels (3.75 and 2.5 mg/ml
taurolidine) and MINO (125 μg/ml minocycline).
Interestingly, the vehicle of the TLG2 gel decreased the adhe-
sion of bacteria (differences after 48 h are 0.99 log10 CFU for
Fig. 1 Killing of selected oral
species and a bacterial mixture
consisting of 12 species
associated with periodontitis by
taurolidine gel formulations and
minocycline microspheres
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Aggregatibacter actinomycetemcomitans Y4 biofilms,
4.50 log10 CFU for Porphyromonas gingivalis ATCC
33277 biofilms, and 1.17 log10 CFU for multi-species bio-
film). TLG2 was more preventive than TLG3 on
Porphyromonas gingivalis ATCC 33277 biofilm formation
(reduction 8.05 vs. 5.91 log10 CFU). Most active was
MINO (reduction 9.16 log10 CFU). TLG2 and TLG3 did
not influence the formation of the multi-species biofilm; in
contrast, MINO decreased the adhesion by 4.44 log10 CFU
after 24 h and by 3.98 log10 CFU after 48 h (Fig. 4).
Discussion
In the present study, the in vitro activity of two taurolidine gel
formulations was compared with those of minocycline micro-
spheres. Taurolidine solutions have been successfully proven
as a catheter-lock agent to prevent catheter-related
bloodstream infections in patients on home parenteral nutri-
tion [18, 19], in central venous catheters in children with can-
cer [20], and in hemodialysis patients [21]. By designing our
study, we aimed to gain more insight on the potential use of
taurolidine as alternative to commonly used topical antimicro-
bials, e.g., minocycline. Minocycline microspheres have been
introduced in periodontal therapy for more than 10 years. Its
efficacy was demonstrated in a large post-marketing study
including 2805 patients in dental practices [22], and its ad-
junctive use to nonsurgical periodontal therapy has been
shown to yield additional clinical benefits (i.e., probing depth
reduction) compared with nonsurgical periodontal therapy
alone [23]. The potential clinical benefit of minocycline mi-
crospheres as an adjunctive to nonsurgical periodontal therapy
was also confirmed in a recent systematic review [24].
Taurolidine in gel formulations showed favorable MIC
values against the included single species with and without se-
rum and were in the range or slightly higher tested before for the
2 % solution [8, 9] meaning that the additives of the gel do not
Fig. 2 Numbers of viable
bacteria of selected oral species
(determined by colony forming
unit counts) after 2 h of exposure
to taurolidine gel formulations
and minocycline microspheres
and subsequent cultivation in
antimicrobial free media
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interfere with the antimicrobial activity of taurolidine. Although
gel formulations may inhibit washout of the drug by the high
turnover of gingival crevicular fluid [13], a flow-out and a de-
creasing concentration of the antimicrobial can be assumed.
Following antimicrobial activity below the MIC in the formula-
tions is a sine qua non condition. The MICs were less or equal
than 10 % of the available concentration within gels except for
themixed population in 25% serumwhere theMICswere 20%
of the 2 % taurolidine gel (4 mg/ml taurolidine).
As shown recently a catheter-lock solution a 2 %
taurolidine solution was more bactericidal than the commonly
used antibiotic vancomycin against Staphylococcus aureus
[25]. In our present study, concentrations up to 10 % of the
formulations were tested in the killing assays and in determi-
nations of a post-antimicrobial activity. This was due in part to
the insolubility of the compounds. On the other hand, this is
more adapted to the in vivo situation in oral cavity where a
diluting effect can be expected very fast. A clear
concentration-dependent activity for taurolidine was
confirmed. But, in contrast to our previous results on a 2 %
solution [12], the mixed population was not eliminated by the
gel formulations. Elimination of multi-species mixtures per se
might be critical. Although tested in high concentrations,
minocycline microspheres did not result in a favorable out-
come in comparison with taurolidine gels.
Post-antimicrobial activity is needed for topical applica-
tions of antimicrobials because a fast diluting effect can be
expected. For example, gingival crevicular fluid in periodon-
titis patients has a volume of up to 1.5 μl and a turnover of up
to 44 μl/h [13]. Although taurolidine gels were able to retard
growth of selected single-species and the multi-species mix-
ture, they were less active than minocycline microspheres on
bacteria when the exposure to the antimicrobial was stopped.
In dentistry and in particular in periodontal therapy, any
antimicrobial should exert activity on biofilms. Models of
single-species and of a 12-species biofilm were tested. In vivo
subgingival biofilm consists of hundreds of different taxa [26];
bacteria co-aggregate, communicate, and transfer DNA [27].
Fig. 3 Effect of taurolidine gels





33277, and on 4.5-day-old
multi-species biofilms of 12
different species associated with
periodontitis. Antimicrobials
were added for 1 h and thereafter
diluted 1:10, and well plates were
incubated for 18 h, before CFU
counts were determined
Clin Oral Invest (2016) 20:597–606 603
Antimicrobials are not as active as against planktonic bacteria
which are associated with limited growth, metabolic activity,
and a polymer matrix around microcolonies [28].
Taurolidine in gel formulations reduced the CFU counts of
an existing single-species biofilm clearly. Aggregatibacter
actinomycetemcomitans Y4 biofilms were eradicated; reduc-
tions were up to 7 log10 CFUwhen acting on Porphyromonas
gingivalis biofi lms. MINO was not as active on
Porphyromonas gingivalis biofilms. Minocycline in compar-
ison with chlorhexidine decreased activity of Porphyromonas
gingivalis biofilm less, but it was more reducing than metro-
nidazole [29]. In other in vitro experiments, 2 % taurolidine
solution reduced viabil i ty by 5–6 log10 CFU in
Staphylococcus aureus, Pseudomonas aeruginosa, and
Candida albicans biofilms [30]. However, confirming a re-
cent report [31], activity of antimicrobials is limited on a
multi-species biofilm. Here, only the 100 % concentration of
a 3 % taurolidine gel was able to reduce the CFU counts by
more than 3 log10. In dental ex vivo biofilm models, the
activity of taurolidine was less than that of chlorhexidine,
but change of vitality was tested already after 2 min of expo-
sure [5]; however, in a study with 15 volunteers, the findings
were similar [32].
Very recent in vitro tests of taurolidine containing catheter-
lock solutions have shown a biofilm preventing activity up
0.25 % [33]. In our study, a biofilm formation was inhibited
but not completely prevented by taurolidine gels and byMINO.
This may be related to the experimental design. Surfaces were
coated; thereafter, bacterial suspension was added. First, the
surface might be the reservoir of the antimicrobial; later, an
equal distribution in the medium (concentration about
0.04 %) can be assumed. In comparison, taurolidine in solution
with a final concentration of 0.1%wasmore active in inhibiting
biofilm formation [12]. This underlines again the necessity of a
high concentration of taurolidine over a longer time period.
Although not acting bactericidal, the vehicle of the TLG2
Fig. 4 Effect of taurolidine gels





33277, and of multi-species
biofilms of 12 different species
associated with periodontitis.
After coating surface with 12.5 %
of taurolidine gels (3.75 and
2.5 mg/ml of taurolidine) and
125 μg/ml of minocycline,
biofilms were formed for 24 and
48 h
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formulation seemed to have a slightly inhibiting effect. This
may be associated to menthol as one excipient of the vehicle.
In this study, antimicrobial activities were investigated. A
general problem in using antimicrobials is the development of
resistance. Increase of MIC values has been demonstrated
in vitro for minocycline [34]. In vivo, an increase of percentage
of tetracycline-resistant streptococci was found after topical use
of minocycline [35]. The mode of action of taurolidine makes
resistance unlikely [25]. After a long-term use of taurolidine as
a catheter-lock solution, no microbial adaption was found [18].
Other, not yet studied, properties of taurolidine might be
also advantageous in periodontal therapy. In an animal model,
wound healing was not impaired after intravenous and intra-
peritoneal application of a 3 % taurolidine solution [36].
Moreover, it appears that taurolidine has certain immunomod-
ulatory effects evidenced by inhibiting ex vivo expression of
inflammatory cytokines (e.g., interleukin(IL)-6 and tumor ne-
crosis factor α) and increasing the release of anti-
inflammatory cytokine IL-10 [37].
Conclusion
Both taurolidine-containing gels are active against bacterial
species associated with periodontitis, even within biofilms.
The clear concentration-dependent activity underlines the ne-
cessity of a high concentration being active for a defined time
at the site of the infection. Additives to the gels (vehicles) may
support a depot or anti-adhesive effect of the antimicrobial.
Our results indicate to continue with the higher concentrated
taurolidine gel (3 %w/v) in follow-up in vitro studies.
The tested taurolidine gels have potential as an adjunctive
antimicrobial treatment in periodontitis and warrant further
evaluation in in vitro and in clinical trials. Nevertheless, com-
plete elimination of multi-species biofilms by taurolidine gels
seems to be impossible and underlines the importance of a
mechanical removal of biofilms prior to application of the
antimicrobial.
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